anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to an injection preparation used for treating cerebral thrombosis and a preparation method thereof. The present invention provides the injection preparation used for treating cerebral thrombosis and the preparation method thereof for patients with cerebral thrombosis, and the injection preparation contains bioactive substances and has the functions of dissolving thrombosis, resisting coagulation, resisting platelet aggregation and improving microcirculation. The preparation method comprises: chromatography by using G75 chromatographic columns, dissolving cobra-venom into phosphate buffer, centrifugal sample charging, column charing, eluting by phosphate buffer, enzyme active peak collection, concentration and freeze drying. The Sephadex-A25 chromatographic columns are used for chromatography, the Tris-HCl buffer with the PH of 7.0 is used for soaking gel and then is charged into the columns, the chromatographic samples are dissolved in the Tris-HCl buffer to charge columns, the NaCl buffer is used for eluting, the enzyme active peaks are collected and then are concentrated and frozen for drying, and dried powder is obtained. The arginine lipase active ingredients of the injection preparation is not lower than 70% of the total weight. The present invention main treats blood vessel thrombotic diseases, such as each period of cerebral thrombosis, encephalatrophy, coronary disease, miocardial infarction, thromboangiitis obliterans, thrombotic phlebitis, Raynaud's disease, aorto arteritis, hyperviscosity, etc.
The objective of this article was to verify the association between domestic violence and obesity and malnutrition in elderly people in Florianópolis, Santa Catarina, Brazil. Cross-sectional study evaluated in the EpiFloripa Elderly cohort in 2013/2014. The outcomes were body mass index (BMI) and abdominal obesity (increased WC). Violence against elderly people was measured using the HawlekSengstock Elder Abuse Screening Test (H-S/EAST) instrument, and IPV using the Conflict Tatics Scales Form R (CTS-1) instrument. Logistic regression and multinomial logistic regression models were used. It was observed that men had a greater chance of abdominal obesity when in situations of violence and in the potential abuse dimension. Women were more likely to have abdominal obesity in the dimension of violation of personal rights or abuse, when they suffered IPV and when they were perpetrators of IPV. In relation to BMI, elderly women in situations of violence were associated with a greater chance of being overweight and those who suffered IPV. On the other hand, men in vulnerable situations were more likely to be underweight. It is concluded that violence against elderly people and IPV generate an asymmetric impact on nutritional status in relation to sex.
The invention belongs to the technical field of medicines and particularly relates to traditional Chinese medicine composition for treating ear eczema. The composition comprises traditional Chinese medicines in parts by weight as follows: 4-6 parts of seeds of Livistonachinensis (Jacq.) R.Br., 4-6 parts of Lysionotus pauciflorus Maxim., 4-6 parts of roots of candolle pimpinella, 4-6 parts of Pendasacme championii Benth., 4-6 parts of Arisaema sikokianum Fuanch., 4-6 parts of Abacopteris multilineata (Wall.) Ching, 4-6 parts of all-grass of winkled marshweed, 4-6 parts of Teucrium pernyi Franch., 4-6 parts of Lespedeza pilosa (Thunb.) Sieb. et Zucc. and 4-6 parts of Coreopsis lanceolata L.. All the traditional Chinese medicines are used together to play effects of clearing away heat, removing toxins, promoting blood circulation to remove meridian obstruction, removing blood stasis, eliminating stagnation and relieving swelling and pain. The composition is used for treating the ear eczema and has the advantages of high cure rate and high total effective rate.
The children were randomized to receive daily zinc sulphate. The elemental zinc dose was 3 mg/ day to children whose weight is less than 10 kg and 7 mg/ day to children whose weight is 10 kg or more.
PURPOSE:To enable formation of ultraviolet ray shielding composite cellular grains, excellent in adsorption performance and fluidity and useful as a decorative substrate by using fine glass particles as a binder, granulating fine particles having ultraviolet ray transmission preventive ability into cellular grains and calcining the resultant grains. CONSTITUTION:Particles formed from a calcined compact of fine particles having ultraviolet ray transmission preventive ability and fine glass particles having a smaller average particle diameter than that of the above-mentioned particles. For example, titanium oxide and zirconium oxide particles are cited as the fine particles having the ultraviolet ray transmission preventive ability (hereinafter referred to as functional fine particles). The average particle diameter varies somewhat according to the use and is normally about 0.1-1mum, especially about 0.1-0.5mum for decorative substrates. Fine glass particles having 0.01-0.5mum average particle diameter are preferably selected as the fine glass particles. The above-mentioned functional fine particles and glass particles are mixed in a specific proportion and the resultant mixture is granulated into grains having a prescribed grain diameter. The resultant grains are subsequently calcined to form the objective grains.
Systems and methods for contextual health assistance are disclosed. Providing contextual health assistance includes normalizing contextual data related to a user based on a big data analytics framework. The contextual data may be received from one or more devices (102, 104). An insight may be generated, based on the normalized contextual data and a user profile corresponding to the user, to classify the user into one of a plurality of dynamically defined classes. The insight may be generated based on deep neural learning. Further, a recommendation for an activity schedule of the user may be determined based on mathematical modeling of the insight, the user profile, and the normalized contextual data. The recommended activity schedule may be provided to a user device (102) for being displayed to the user.
The aim of our study was to evaluate the efficacy of this therapy in patients with refractory primary immune thrombocytopenia. It is crucial to develop alternative treatment methods for this patient group in order to achieve better response. This combination therapy combines two different mechanisms of action, which is promising in terms of targeting pathophysiology of immune thrombocytopenia. We conducted a retrospective study, which included all patients who were diagnosed with refractory primary immune thrombocytopenia and received TPO-RA and rituximab at the General Hematology Department, Copernicus Memorial Hospital in Lodz, Poland. We assessed the response, time to response and treatment-free remission (TFR). After 1 month of treatment, the complete response (CR1, PLT >100 g/l) was achieved in 62.5% patients, and response (R1, PLT >30 g/l) was achieved in 62.5% patients. The median PLT was 175 × 10 9 /l. Within 1 month of treatment, 87.5% of patients achieved TFR. Adequately, after 6 months, CR6 and R6 was 62.5 and 75%. The median PLT was 182 × 10 9 /l. Treatment-free remission 6 months after completion was in 50% of patients. The study group achieved response to treatment, which suggests that combination of TPO-RA and rituximab is effective and relatively well tolerated. Prospective study on larger group of patients is needed to better evaluate the efficiency and safety of this treatment.
Left ventricular assist devices (LVADs) are an increasingly used strategy for the management of patients with advanced heart failure. Although these devices effectively improve survival, atrial and ventricular arrhythmias are common with a prevalence of 20-50% at one year after LVAD implantation. Arrhythmias predispose these patients to additional risk and are associated with considerable morbidity from recurrent implantable cardioverter-defibrillator shocks, progressive failure of the unsupported right ventricle, and herald an increased risk of mortality. Management of patients with arrhythmias and LVAD differs in many aspects from the general population heart failure patients. These include ruling out the reversible causes of arrhythmias that in LVAD patients may include mechanical irritation from the inflow cannula and suction events. For patients with symptomatic arrhythmias refractory to medical treatment, catheter ablation might be relevant. There are specific technical and procedural challenges perceived to be unique to LVAD-related ventricular tachycardia (VT) ablation such as vascular and LV access, signal filtering, catheter manoeuvrability within decompressed chambers, and electroanatomic mapping system interference. In some patients, the arrhythmogenic substrate might not be readily accessible by catheter ablation after LVAD implantation. In this regard, the peri-implantation period offers a unique opportunity to surgically address arrhythmogenic substrate and suppress future VT recurrences. This document aims to address specific aspects of the management of arrhythmias in LVAD patients focusing on anti-arrhythmic drug therapy and ablations.
<P>PROBLEM TO BE SOLVED: To perform suitable hypouricemic effects while inhibiting side effects as much as possible.  <P>SOLUTION: A uric acid level reducing agent includes Pleurotus eryngii var. tuoliensis or an extract of the Pleurotus eryngii var. tuoliensis as an active ingredient. Preferably, the Pleurotus eryngii var. tuoliensis undergoes drying treatment or processing treatment.  <P>COPYRIGHT: (C)2011,JPO&INPIT
A primary amine of formula (II): R1-O-CH-CHOH-CH2-NH2 is reacted with an aromatic aldehyde of formula (III) : R2-CH=O, pref. anisaldehyde to form a Schiff base (IV) : R1-O-CH2-CHOH-CH2-N=CH-R2 which is hydrogenated catalytically in the presence of acetone, forming cpds. (I) : R1-O-CH2-CHOH-CH2-NH-CHCH3-CH3; where R1 = napthyl or tolyl; R2 = phenyl, opt. substd. with one or more methoxy or ethoxy or with one methylenedioxy or nitro. (I) are known cpds. with beta-adrenergic-blocking action. They are pref. used in the treatment of arrhythmias and in the prevention of angina pectoris. The process gives (I) in high yield and purity. Conditions used are mild and the starting materials are easily accessible or prepd. No purificn. of (I) is necessary after hydrogenation, as the usual impurity formed in (II) is removed by reaction with (III).
Control subjects will use the electronic monitoring devices just like the intervention arm, but will receive standard of care. They will not receive personalized cell phone reminder messages whenever they fail to take a dose within 30 minutes of dose time, and they will not have access to the summaries of their previous month's behavior for use in interactive counseling sessions, though they will be encouraged to engage in counseling.
OBJECTIVE: Incomplete healing after cesarean section (CS) can result in isthmocele formation. When suturing the uterus, fully folding the wound lips may embed the endometrial layer into the myometrium, leading to isthmocele development. Hence, this study aimed to compare the effects of endometrial and non-endometrial suturing on isthmocele development.
MATERIAL AND METHODS: This randomized controlled trial included 274 patients. Women who underwent primary CS were randomly allocated to one of the two study groups: endometrial suturing and non-endometrial suturing. The primary outcome was isthmocele rate at postpartum 6 months. Secondary outcomes were the volume of the isthmocele, thickness of the residual myometrium, menstrual irregularities (intermenstrual spotting), and the relationship between the isthmocele and uterine position.
RESULTS: A total of 159 patients (81 in the endometrial suturing group and 78 in the non-endometrial suturing group) were analyzed. The incidence of isthmocele was significantly lower in the non-endometrial suturing group than in the endometrial suturing group (12 [15.4%] vs. 24 [29.6%] patients; p = 0.032). Menstrual irregularities, such as intermenstrual spotting, were significantly higher in the endometrial suturing group than in the non-endometrial group (p = 0.019).
CONCLUSION: Uterine closure with non-endometrial suturing was associated with significantly lower isthmocele development and less intermenstrual spotting compared to that with endometrial suturing.
INTRODUCTION: One population that presents an important vulnerability to stress is that of university students, facing several stressors, such as academic demands, time pressure and social adjustments. Medical students in particular may face additional challenges such as heavy workload, time commitment and the number of tests and assessments as well as the pressures of a clinical setting. Some highly successful programs in stress management are based on the principle of Mindfulness. On the other hand, Positive Psychology brings a new paradigm in terms of mental and emotional health, seeking to promote human development through the development of virtues, quality of life and well-being, instead of just treating disease. In the modern world not all people are willing to attend classroom training for several reasons. In this sense, a program offered in mobile application can be considered an interesting alternative for professionals that not only want to reduce stress-related symptoms, but also promote well-being.

MAIN OBJECTIVES: Evaluate the effects of a well-being program compared to a control program, both served on mobile applications, in reducing stress, increasing well-being and improving emotional regulation in a sample of medical students.

METHOD: For this purpose, 300 students of the undergraduate medical course of Albert Einstein Israelite Faculty. Participants will be randomized into groups of 150 each, half to the control group (CG) and the other half to the intervention group (IG). The IG will participate in the Flourish App Program, for 8 weeks, while the CG will have access to a control application. Then, after the evaluations, the CG will participate in the Flourish App Program, while the first group will not participate in any intervention. Before starting the program, after 4 and 8 weeks of the program, questions will be applied to assess the stress and well-being levels of participants in general and in relation to work. In addition, before and after each training period, questions will be applied to assess the stress and well-being levels of participants at the moment. Also, the Perceived Stress Scale, the 5-item World Health Organization Well-Being Index - WHO-5, the Mindful Attention Awareness Scale, the Self-Compassion Scale and the Difficulties in Emotion Regulation Scale will be applied too. Finally, at the end of the program, the Mobile Application Rating Scale - MARS will be applied.
OBJECTIVE: To study the prevalence and clinical features of cervical dystonia in Parkinson's disease (CD-PD).
BACKGROUND: PD features various forms of dystonia, including CD. Yet, the prevalence and clinical features of CD in PD patients are not well-characterized.
METHODS: We conducted a single site, prospective study where consecutively evaluated PD patients were examined for the presence of CD to ascertain its prevalence. For each case of CD-PD, a standardized questionnaire assessing demographic and clinical features was completed. Statistical analysis was performed to compare CD-PD characteristics to those of a previously published large idiopathic CD cohort.
RESULTS: Of 301 consecutive PD patients evaluated, 28 (9.3 %) had CD, far surpassing estimates of CD prevalence in the general population. This CD-PD cohort was predominantly male (71 %) with a mean age of 70.9 ± 8.1 years. The mean duration of PD was 10.4 ± 6.7 years. In most cases (n = 19, 68 %), CD developed after the onset of PD. Five patients reported dystonia improvements in response to levodopa, while none reported medication-induced worsening. In contrast to CD-PD, those with ICD (n = 209) were on average younger (59.7 ± 10.1) and mostly female (74 %, p < 0.001). In addition, CD-PD was overall less severe as measured by the Global Dystonia Rating Scale (GDRS) (p = 0.002) and featured less head tremor and pain.
CONCLUSION: Our findings indicate CD is overrepresented in PD compared to the general population and has clinical features distinct from those of ICD. These results justify larger, more comprehensive studies of CD-PD to better understand its frequency, pathophysiology, clinical characteristics, and associated risk factors.
The Vietnamese Ministry of Health has a clinical grading system. Grade 1 disease is uncomplicated and are not admitted to hospital. Grade 2 and above are admitted to hospital with clinical features of neurological or systemic involvement. Grade 2 is split into Grade 2a and 2b depending if neurological manifestations such as myoclonus have been witnessed by the parents or by a health professional. In total, it is anticipated that 125 Grade 2a and 125 Grade 2b and 100 more severe Grade 3 and 4 will be recruited over one year. A subset who agree for brain magnetic resonance imaging (MRI) will also have a scan done during their hospital admission.
AIMS: Patients with HFrEF and worsening HF events (WHFE) are at particularly high risk and urgently need disease-modifying therapy. CHART-HF assessed treatment patterns and reasons for medication decisions among HFrEF patients with and without WHFE.
METHODS AND RESULTS: CHART-HF collected retrospective electronic medical records of outpatients with HF and EF < 45% between 2017-2019 from a nationwide panel of 238 cardiologists (458 patients) and the Geisinger Health System (GHS) medical record (1000 patients). The index visit in the WHFE cohort was the first outpatient cardiologist visit ≤6 months following the WHFE, and in the reference cohort was the last visit in a calendar year without WHFE. Demographic characteristics were similar between patients with and without WHFE in both the nationwide panel and GHS. In the nationwide panel, the proportion of patients with versus without WHFE receiving ≥50% of guideline-recommended dose on index visit was 35% versus 40% for beta blocker, 74% versus 83% for ACEI/ARB/ARNI, and 48% versus 49% for MRA. The proportion of patients receiving ≥50% of guideline-recommended dose was lower in the GHS: 29% versus 34% for beta-blocker, 16% versus 31% for ACEI/ARB/ARNI, and 18% versus 22% for MRA. For patients with and without WHFE, triple therapy on index date was 42% and 44% of patients from the nationwide panel, and 14% and 17% in the GHS. Comparing end of index clinic visit with 12-month follow-up in the GHS, the proportion of patients on no GDMT increased from 14% to 28% in the WHFE cohort and from 14 to 21% in the non-WHFE group.
CONCLUSIONS: Major gaps in use of GDMT, particularly combination therapy, remain among US HFrEF patients. These gaps persist during longitudinal follow-up and are particularly large among patients with recent WHFE.
HIV infected adolescents who require therapy face a lifetime of antiretroviral treatment. Highly active antiretroviral therapy (HAART) is associated with short- and long-term complications, and concerns are mounting about the cumulative effect of these complications as adolescents enter the third and fourth decade of life. A management strategy that can suppress the virus and decrease overall drug exposure is needed. In addition, the scheduling requirements for antiretroviral therapies interfere with the socialization and independence that an adolescent must accomplish to gain skills for a successful adult life. Not surprisingly, nonadherence to prescribed medications is common in teens. This multicenter, prospective, proof of concept trial will evaluate Short Cycle Therapy (SCT) in adolescents with sustained viral suppression of at least 6 months. While maintenance of viral load suppression can be viewed as either a safety or efficacy endpoint, the trial is constructed as an assessment of safety.

Eligible participants who have been on standard HAART therapy consisting of a Protease Inhibitor will switch to SCT therapy(4 days on treatment, 3 days off treatment each week) at entry. Participants will be seen in the clinic every other Monday during the first month, then monthly up to 24-weeks and then once every two months until the end of the 48-week study period. Plasma HIV RNA levels and CD4 cell counts will be performed at every visit. Medication adherence by self-report will be conducted every 2 weeks until week 24 and every 4-weeks thereafter until week 48. Fasting serum triglycerides and cholesterol will be measured at baseline, at week 24 and at the end of the study.
Participants will ingest oral nisin once daily starting two weeks before planned complete OSCC resection surgery and will continue once daily administration for 6 additional months post-surgery (concurrent with adjuvant radiation/chemoradiation, for participants whose routine treatment plan includes adjuvant therapy). Nisin will be temporarily withheld at the time of OSCC resection surgery while the participant is under inpatient care. The dose level will be determined by the outcomes in Phase 1 (RP2D), with dose modification permitted for toxicity management or intolerability.
A composition and a method for use in suppressing growth and/or proliferation of cancer cells in vivo and in vitro is provided. The composition includes an alcoholic lignan extract prepared from coniferous species optionally in combination with betulonic acid or betulinic acid. The composition inhibits growth and/or proliferation of at least prostate and melanoma cancer cells in vitro. Combination of the alcoholic lignan extract and betulonic or betulinic acid has a synergic effect specifically in inhibition of melanoma and prostate cancer cell proliferation and toxicity. Oral daily administration of the composition decreases or in some cases abolishes tumors of patients with breast cancer, brain cancer or colon cancer. The composition is suitable for use in cancer treatment in pet animals as well.
The tetracyclines are broad spectrum anti-microbial agents that are widely used in human and veterinary medicine. The widespread use of tetracyclines for therapeutic purposes has led to the emergence of resistance to these antibiotics. Therefore, there is need for new tetracycline compounds with improved antibacterial activities. The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a compound represented by Structural Formula (I) having R4 and R4’ = ethyl, R5 = H, R6 and R6’ = H, R1 = CF3, R3 = H, and X = C(R2), wherein R2 is 2-pyrrolidinyl. This compound is used to treat a variety of bacterial infections, including respiratory and skin bacterial infections.
PROBLEM TO BE SOLVED: To produce the subject base material by irradiating active energy rays having specific wave lengths on a composition consisting of a monomer having an ethylenic unsaturated bond, a specific agent and a specific photopolymerization initiator to photoset the composition without, decomposing nor deteriorating the agent. SOLUTION: A composition consisting of (A) a monomer having an ethylenic unsaturated bond, (B) an agent (preferably, ketoprofen) being decomposed or deteriorated with active energy rays of <=400nm in wave lengths and (C) a photopolymerization initiator enabling the initiation of polymerization with active energy rays of >=400nm in wave lengths is irradiated with active energy rays free from rays of <=400nm in wave length. Further, the component C is preferably an acylphosphine oxide compound of the formula (R1 is a 1-18C alkyl, phenyl, etc.; R2 is a 1-18C alkyl, cyano, etc.; R3 is a 1-18C alkyl, phenylvinyl, etc.) (e.g. 2,4,6-trimethylbenzoyldiphenylphosphine oxide).